Skip to main content

Recent Advances in Pharmacokinetics of Polymeric Excipients Used in Nanosized Anti-Cancer Drugs

Buy Article:

$55.00 plus tax (Refund Policy)

The efficacy of drug delivery systems using nanoparticles to enhance the pharmacokinetic properties of drugs has been confirmed in both preclinical trials and clinical settings. A nanosized drug system has improved efficacy, reduced side effects and clearance, increased cellular uptake and prolonged time in circulation. This article will focus recent studies of the pharmacokinetic behavior of such systems as poly(ethylene glycol) and polyamidoamine. Their derivatives are also analyzed. Additionally, some diseases with very good responsiveness are aslo reported.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Dendrimer; doxorubicin; liposome; nanomedicine; pharmacokinetic; poly(ethylene glycol)

Document Type: Research Article

Publication date: 2009-10-01

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more